Deregulated Expression of Aurora Kinases Is Not a Prognostic Biomarker in XXXX @entity1 .

@entity1 @entity3557 @entity5 @entity875 @entity16511 @entity3 @entity817 @entity259
UNASSIGNED: A number of reports indicated that @entity875 or @entity16511 overexpression represented a negative prognostic factor in several @entity1 @entity5 . In @entity259 tissues a deregulated expression of Aurora kinases has been also demonstrated, butno information regarding its possible prognostic role in differentiated @entity259 is available. Here, weevaluated @entity875 and @entity16511 mRNA expression and its prognostic relevance in a series of 87 @entity3557 ( @entity3557 ), with a median follow-up of 63 months. The analysis of @entity875 and @entity16511 mRNA levels in @entity3557 tissues, compared to normal matched tissues, revealed that their expression was either up- or down-regulatedin the majority of @entity5 tissues. In particular, @entity875 and @entity16511 mRNA levels were altered, respectively, in 55 (63.2%) and 79 (90.8%) out of the 87 @entity3557 analyzed.A significant positive correlation between @entity875 and @entity16511 mRNAswas observed (p=0.001). The expression of both Aurora genes was not affected by the BRAFV600E mutation. Univariate, multivariate and Kaplan-Mayer analyses documented the lack of association between @entity875 or @entity16511 expression and clinicopathological parameterssuch as gender, age, @entity5 size, histology, TNM stage, lymph node @entity3 and @entity817 status as well asdisease recurrences or disease-free interval. Only @entity16511 mRNA was significantly higher in T(3-4) tissues, with respect to T(1-2) @entity3557 tissues. The data reported here demonstrate that the expression of Aurora kinases is deregulated in the majority of @entity3557 tissues, likely contributing to @entity3557 progression. However, differently from other @entity1 solid cancers, detection of @entity875 or @entity16511 mRNAs is not a prognostic biomarker inPTC @entity1 .
